Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

We evaluated standard-of-care (SOC) treatment with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients with acute myeloid leukemia (AML) harboring internal tandem duplication (ITD) in FLT3. Adults (aged 18–70 years) who received al...

Descripción completa

Detalles Bibliográficos
Autores principales: Maziarz, Richard T., Levis, Mark, Patnaik, Mrinal M., Scott, Bart L., Mohan, Sanjay R., Deol, Abhinav, Rowley, Scott D., Kim, Dennis D. H., Hernandez, Daniela, Rajkhowa, Trivikram, Haines, Kelly, Bonifacio, Gaetano, Rine, Patrice, Purkayastha, Das, Fernandez, Hugo F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113057/
https://www.ncbi.nlm.nih.gov/pubmed/33288862
http://dx.doi.org/10.1038/s41409-020-01153-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113057/
https://www.ncbi.nlm.nih.gov/pubmed/33288862
http://dx.doi.org/10.1038/s41409-020-01153-1

Ejemplares similares